![Manuel Opitz](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Postes actifs de Manuel Opitz
Sociétés | Poste | Début | Fin |
---|---|---|---|
Mecuris GmbH
![]() Mecuris GmbH Commercial Printing/FormsCommercial Services Mecuris GmbH operates a software platform for automatic generation of patient-customized orthoses and prosthetic designs. The company was founded by Manuel Opitz, Wolf-Peter Werner, Felix Gundlack, Jannis Breuninger and Simon Weidert and is headquartered in Munich, Germany. | Fondateur | 22/06/2016 | - |
Corporate Officer/Principal | 22/06/2016 | - | |
Deepeye Medical GmbH
![]() Deepeye Medical GmbH Information Technology ServicesTechnology Services Deepeye Medical GmbH is a German medical company that aims to address the issue of millions going blind every year despite effective retinal therapy. The private company is located in Germany. The company's co-founders have developed a 2nd-opinion-approach using AI to scale their solution. The company also offers Deepeye® research, which unlocks the future of clinical studies. | Directeur Général | 01/01/2021 | - |
Fondateur | 01/01/2021 | - |
Historique de carrière de Manuel Opitz
Statistiques
Internationale
Allemagne | 3 |
Opérationnelle
Founder | 2 |
Corporate Officer/Principal | 1 |
Chief Executive Officer | 1 |
Sectorielle
Commercial Services | 2 |
Technology Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 2 |
---|---|
Mecuris GmbH
![]() Mecuris GmbH Commercial Printing/FormsCommercial Services Mecuris GmbH operates a software platform for automatic generation of patient-customized orthoses and prosthetic designs. The company was founded by Manuel Opitz, Wolf-Peter Werner, Felix Gundlack, Jannis Breuninger and Simon Weidert and is headquartered in Munich, Germany. | Commercial Services |
Deepeye Medical GmbH
![]() Deepeye Medical GmbH Information Technology ServicesTechnology Services Deepeye Medical GmbH is a German medical company that aims to address the issue of millions going blind every year despite effective retinal therapy. The private company is located in Germany. The company's co-founders have developed a 2nd-opinion-approach using AI to scale their solution. The company also offers Deepeye® research, which unlocks the future of clinical studies. | Technology Services |
- Bourse
- Insiders
- Manuel Opitz
- Expérience